Observational studyEuropean journal of pediatrics2026
Universal saliva PCR screening for congenital cytomegalovirus identifies asymptomatic infections with neuroimaging abnormalities in a prospective neonatal cohort.
Observational study in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Congenital cytomegalovirus (cCMV) infection is the leading non-genetic cause of sensorineural hearing loss and an important cause of neurodevelopmental impairment [1-3, 6-14]. Targeted screening strategies frequently fail to detect infected infants who are asymptomatic at birth but remain at risk for late sequelae [9]. This study aims to evaluate the diagnostic yield of universal saliva PCR screening compared with targeted screening strategies and to describe neuroimaging findings in identified cases. We conducted a prospective observational cohort study including 4000 neonates born at ARNAS Civico di Palermo, Italy, between July 2023 and September 2025. All neonates underwent saliva PCR screening on the second day of life. Positive results were confirmed by urine PCR. Infants with confirmed infection underwent cranial ultrasound, brain MRI, ophthalmologic examination, and audiological assessment. The prevalence of cCMV infection was 0.2% (8/4000). Using targeted screening criteria based on symptoms or failed hearing screening, only 62.5% (5/8) of infections would have been detected. Consequently, 37.5% (3/8) represented infections in asymptomatic infants who passed hearing screening. Neuroimaging abnormalities were observed in all confirmed cases.
conclusionUniversal screening improves diagnostic yield and identifies clinically asyntomatic infections with early neuroimaging abnormalities, supporting broader neonatal surveillance strategies. WHAT IS KNOWN: • cCMV infection is a leading non-genetic cause of childhood hearing loss and neurodevelopmental impairment. Only ~10% of infected neonates are symptomatic at birth; targeted screening often misses asymptomatic infants. Saliva PCR is a practical and accurate diagnostic tool for early detection. WHAT IS NEW: • Universal saliva PCR screening detected 37.5% more infections than targeted strategies. All infected infants, including asymptomatic cases, showed early neuroimaging abnormalities, highlighting neurological involvement.
Indexed as
Identifiers
42283916What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.